Skip to main content
Erschienen in: Clinical and Translational Oncology 6/2018

20.11.2017 | Research Article

Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study

verfasst von: M. Sureda, J. Rebollo, E. Mª. Martínez-Navarro, F. J. Fernández-Morejón, J. Farré, V. Muñoz, P. Bretcha-Boix, M. Duarte, R. G. Manzano, A. Crespo, M. del Carmen Redal, B. Valenzuela, A. Brugarolas

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The present study evaluates the massive study of gene expression in metastatic breast carcinoma (MBC) patients using microarray gene expression profiling (MAGE) complemented with conventional sequencing, immunohistochemistry (IHC) and fluorescent “in situ” hybridization (FISH), seeking to optimize the treatment in a subset of heavily pretreated patients and with limited life expectancy.

Patients, material and methods

MBC patients in hormone therapy progression with survival expectancy of at least 3 months (m) have been included. The MAGE contains gene probes representing genes known to potentially interact with available drugs as cited in the literature.

Results

Thirty-nine procedures were performed from October 2010 to April 2016. Within the 30 evaluable procedures, considering all hormonal manipulations as a single line, the patients had received a median of 4 treatment lines prior to MAGE (range 1–7). Progression was observed in 6 cases, stable disease (SD) in 7 cases and partial response (PR) in 16 cases, which implies a clinical benefit rate (SD + PR) of 76%. Actuarial median progression-free survival (PFS) was 6 m (95% CI 2.5–9.5) in patients with clinical benefit. The median overall survival (OS) for the entire series was 11 m (95% CI 2.2–19.8).

Conclusion

Data presented here indicate that the use of MAGE provides relevant information to establish personalized treatment in frail patients with limited life expectancy in which therapeutic futility is a particularly difficult burden to assume.
Literatur
1.
Zurück zum Zitat Sánchez MJ, Payer T, De Angelis R, Larrañaga N, Capocaccia R, Martínez C, et al. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;21(Suppl 3):iii30–6.PubMed Sánchez MJ, Payer T, De Angelis R, Larrañaga N, Capocaccia R, Martínez C, et al. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;21(Suppl 3):iii30–6.PubMed
2.
Zurück zum Zitat Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130:609–14.CrossRefPubMed Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130:609–14.CrossRefPubMed
3.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormone therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormone therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRef
4.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121:2750–67.CrossRefPubMedPubMedCentral Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121:2750–67.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Masuda H, Baggerly KA, WangY Zhang Y, González-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–40.CrossRefPubMed Masuda H, Baggerly KA, WangY Zhang Y, González-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–40.CrossRefPubMed
6.
Zurück zum Zitat Planchard D, Besse B, Groen HJ, Planchard D, Souquet PJ, Quoix E, Balk CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF (V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984–93.CrossRefPubMedPubMedCentral Planchard D, Besse B, Groen HJ, Planchard D, Souquet PJ, Quoix E, Balk CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF (V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984–93.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F. Dabrafenib in patients with BRAF (V600E)-positive advanced non-small cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:642–50.CrossRefPubMedPubMedCentral Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F. Dabrafenib in patients with BRAF (V600E)-positive advanced non-small cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:642–50.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Barlesi F. Dual-targeted therapy wit trastuzumab and lapatinib in treatment of refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer(HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.CrossRefPubMed Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Barlesi F. Dual-targeted therapy wit trastuzumab and lapatinib in treatment of refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer(HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.CrossRefPubMed
9.
Zurück zum Zitat Rebollo J, Sureda M, Martínez EM, Fernández-Morejón FJ, Farré J, Muñoz V, et al. Gene expression profiling of tumors from heavily pretreated patients with metastatic cancer for the selection of therapy: a pilot study. Am J Clin Oncol. 2017;40:140–5.CrossRefPubMed Rebollo J, Sureda M, Martínez EM, Fernández-Morejón FJ, Farré J, Muñoz V, et al. Gene expression profiling of tumors from heavily pretreated patients with metastatic cancer for the selection of therapy: a pilot study. Am J Clin Oncol. 2017;40:140–5.CrossRefPubMed
10.
Zurück zum Zitat Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877–83.CrossRef Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28:4877–83.CrossRef
11.
Zurück zum Zitat Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2014;147:579–88.CrossRefPubMed Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2014;147:579–88.CrossRefPubMed
12.
Zurück zum Zitat Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, et al. Phase I clinical trials in 85 patients with gynecologic cancer: the M.D. Anderson Cancer Center experience. Gynecol Oncol. 2010;117:467–72.CrossRefPubMedPubMedCentral Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, et al. Phase I clinical trials in 85 patients with gynecologic cancer: the M.D. Anderson Cancer Center experience. Gynecol Oncol. 2010;117:467–72.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat De Mattos-Arruda L, Rodon J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist. 2013;18:1180–8.CrossRefPubMedPubMedCentral De Mattos-Arruda L, Rodon J. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist. 2013;18:1180–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment of cancer. Clin Chem. 2013;59:1447–56.CrossRefPubMed Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment of cancer. Clin Chem. 2013;59:1447–56.CrossRefPubMed
16.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerst J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerst J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
17.
Zurück zum Zitat Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res. 2017;23:3610–8.CrossRefPubMedPubMedCentral Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res. 2017;23:3610–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study
verfasst von
M. Sureda
J. Rebollo
E. Mª. Martínez-Navarro
F. J. Fernández-Morejón
J. Farré
V. Muñoz
P. Bretcha-Boix
M. Duarte
R. G. Manzano
A. Crespo
M. del Carmen Redal
B. Valenzuela
A. Brugarolas
Publikationsdatum
20.11.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 6/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1789-9

Weitere Artikel der Ausgabe 6/2018

Clinical and Translational Oncology 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.